Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in AC therapeutics.

There will be more than 1 billion prevalent cases of AC in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AC.

The innovator marketed drugs space for AC mainly consists of dual-acting antihistamines and mast cell inhibitors.

R&D activity in AC is promising with four drugs in Phase III and 10 drugs in Phase II of development.

Clinical trial space in AC mainly includes commercial sponsors, with the US emerging as the key country for conducting Phase III trials.

Two strategic alliances and one merger & acquisition involving companies developing AC assets were successfully completed in the past two years.

Scope

GlobalData’s Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include-
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the AC market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Key Findings
  • Disease Overview
  • Epidemiology Overview
    • Epidemiology Overview: Total Prevalent Cases of AC in 2023 and 2028
  • Treatment Overview
    • Treatment Guidelines
    • Treatment Algorithm
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in AC
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drug Profile: Aytu BioPharma/Tris Pharma’s Karbinal ER
    • Marketed Drug Profile: Eyevance Pharmaceuticals’s Zerviate
    • Marketed Drug Profile: Ocular Therapeutix’s Dextenza
    • Marketed Drug Profile: Johnson & Johnson’s Ketotifen Fumarate
    • Marketed Drug Profile: Novartis’s Pazeo
    • Marketed Drug Profile: Boehringer Ingelheim’s Alesion/Alesion LX/Elestat/ Purivist/Relestat
    • Marketed Drug Profile: Stallergenes Greer’s Alustal 5 Grasses and Rye/Alustal Beifuss/Oralair/Oraleyr/Phostal 5 Grasses and Rye/Phostal Beifuss
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - Annual Therapy Cost
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Late-to-mid-Stage Pipeline Drugs in AC
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in AC
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Ophthalmology and in AC
  • Clinical Trials Assessment
    • Clinical Trials in AC - Historical Overview
    • Clinical Trials in AC - Overview by Phase
    • Clinical Trials in AC - Overview by Status
    • Clinical Trials in AC - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in AC - Trials with a Virtual Component
    • Clinical Trials in AC - Number of Trials by Geography
    • Clinical Trials in AC - Single-Country and Multinational Trials by Region
    • Clinical Trials in AC - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in AC - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in AC - Overview by Endpoint Status
    • Clinical Trials in AC - Overview by Race and Ethnicity
    • Clinical Trials in AC - Enrollment Data
    • Clinical Trials in AC - Overview of Sites by Geography
    • Clinical Trials in AC - Top 20 Countries for Trial Sites
    • Clinical Trials in AC - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for AC
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in AC by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in AC
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in AC
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in AC
  • Appendix
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings